Description: Biocon Limited, a biopharmaceutical company, manufactures pharmaceuticals, and medicinal chemical and botanical products. The company operates through Small Molecules, Biologics, Branded Formulations, and Research Services segments. It focuses in the areas of diabetes, oncology, immunology, dermatology, ophthalmology, neurology, rheumatology, and inflammatory diseases. The company provides biosimilars comprising recombinant human insulin, insulin glargine, biosimilar trastuzumab, and other biopharmaceuticals; small molecules, such as active pharmaceutical ingredients and generic formulations; and branded formulation products under the Insugen, Basalog, BIOMAb EGFR, CANMAb, and ALZUMAb brands. It is also involved in the integrated discovery, development, and manufacturing services for small and large molecules, antibody-drug conjugates, and oligonucleotides. The company serves customers in approximately 120 countries. Biocon Limited was founded in 1978 and is headquartered in Bengaluru, India.
Home Page: www.biocon.com
20th KM, Hosur Road
Bengaluru,
560100
India
Phone:
91 80 2808 2808
Officers
| Name | Title |
|---|---|
| Ms. Kiran Mazumdar-Shaw B.Sc., B.Sc (Hons) | Founder & Exec. Chairperson |
| Mr. Siddharth Mittal | MD, CEO & Director |
| Mr. Mayank Verma | Company Sec. & Compliance Officer |
| Mr. Anupam Jindal | Chief Financial Officer |
| Mr. Indranil Sen | VP of Fin. & Accounts |
| Mr. Saurabh Paliwal | Head of Investor Relations |
| Mr. Amitava Saha | Pres of HR |
| Mr. Sandeep Rao M.Sc., PGDM | Sr. VP |
| Mr. B. S. V. Prasad | Chief Operating Officer of Biocon Generics & APIs |
| Mr. Nehal Vora | Commercial Head of Biocon Global APIs & Sr. VP |
Exchange: BSE
Country: IN : India
Currency: Indian Rupee (INR)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 73.2496 |
| Price-to-Book MRQ: | 7.5633 |
| Price-to-Sales TTM: | 7.8273 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 12609 |